London, UK (PRWEB UK) 21 August 2013
Alex Kudrin, Medical Assessor, Biological Licensing, who will be making the address at the summit, released a statement on the future of clinical oncology and his participation:
"The cancer vaccine conference will bring together experts from academia and industry in order to discuss most recent developments in a highly promising field of cancer immunotherapeutics. The recent success of Yervoy and Provenge combined with sustained clinical pipeline of cancer vaccine candidates illustrate that we are entering a new era of clinical oncology where we can truly change the outcome in cancer patients and improve the quality of oncology care. Experts from all walks of life will be able to hear on the most up-to-date trends in regulatory, development and commercialization of cancer immunotherapeutics and what opportunities and challenges exist in the field."
Alex will be providing delegates with a global overview of cancer vaccines with a spot light on phase II-III studies, FDA and EMA conduct and implications of new immunotherapies on health care and reimbursement.
The MHRA will be joined by many more leading industry experts at the much anticipated return of SMi's 2nd annual Cancer Vaccines Conference which is now just under 4 weeks away.
Speakers will include:
The event aims to be a unique platform for learning about the new advances in cancer vaccines, presenting attendees with latest developments and innovations in this ever changing field. Event highlights include:
Cancer Vaccines | 18 – 19 September 2013, London UK
For further information on this event visit http://www.cancervaccinesevent.com